Last reviewed · How we verify
SB-756050 immediate release capsule — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
SB-756050 immediate release capsule (SB-756050 immediate release capsule) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SB-756050 immediate release capsule TARGET | SB-756050 immediate release capsule | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SB-756050 immediate release capsule CI watch — RSS
- SB-756050 immediate release capsule CI watch — Atom
- SB-756050 immediate release capsule CI watch — JSON
- SB-756050 immediate release capsule alone — RSS
Cite this brief
Drug Landscape (2026). SB-756050 immediate release capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/sb-756050-immediate-release-capsule. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab